Zyx Sitruuna 3 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

zyx sitruuna 3 mg imeskelytabletti

viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini

Strepsils Sitrus 1.2 mg / 0.6 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

strepsils sitrus 1.2 mg / 0.6 mg imeskelytabletti

reckitt benckiser healthcare (scandinavia) a/s - dichlorbenzylalcohol, amylmetacresol - imeskelytabletti - 1.2 mg / 0.6 mg - diklooribentsyylialkoholi

Zyx Eukalyptus 3 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

zyx eukalyptus 3 mg imeskelytabletti

viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini

Zyx Appelsiini & Hunaja 3 mg imeskelytabletti Suomi - suomi - Fimea (Suomen lääkevirasto)

zyx appelsiini & hunaja 3 mg imeskelytabletti

viatris oy - benzydamine hydrochloride - imeskelytabletti - 3 mg - bentsydamiini

Zerbaxa Euroopan unioni - suomi - EMA (European Medicines Agency)

zerbaxa

merck sharp & dohme b.v.  - ceftolozane sulfaatti -, natrium-tatsobaktaami - bakteeri-infektiot - systeemiset bakteerilääkkeet, - zerbaxa is indicated for the treatment of the following infections in adults:complicated intra abdominal infections;acute pyelonephritis;complicated urinary tract infections;hospital-acquired pneumonia (hap), including ventilator associated pneumonia (vap). on otettava huomioon viralliset ohjeet antibioottien tarkoituksenmukaisesta käytöstä.

Horse Allo 20 Euroopan unioni - suomi - EMA (European Medicines Agency)

horse allo 20

centauri biotech sl - allogeenisen hevosen rasvakudoksen johdettu mesenkymaaliset kantasolut - hevoset - hoitoon nivelrikko aikuisilla kuin elintarviketuotantoon hevoset.

Blincyto Euroopan unioni - suomi - EMA (European Medicines Agency)

blincyto

amgen europe b.v. - blinatumomab - prekursorisolujen lymfoblastinen leukemia-lymfooma - antineoplastiset aineet - blincyto is indicated as monotherapy for the treatment of adults with cd19 positive relapsed or refractory b precursor acute lymphoblastic leukaemia (all). patients with philadelphia chromosome positive b-precursor all should have failed treatment with at least 2 tyrosine kinase inhibitors (tkis) and have no alternative treatment options. blincyto is indicated as monotherapy for the treatment of adults with philadelphia chromosome negative cd19 positive b-precursor all in first or second complete remission with minimal residual disease (mrd) greater than or equal to 0. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with philadelphia chromosome negative cd19 positive b precursor all which is refractory or in relapse after receiving at least two prior therapies or in relapse after receiving prior allogeneic haematopoietic stem cell transplantation. blincyto is indicated as monotherapy for the treatment of paediatric patients aged 1 year or older with high-risk first relapsed philadelphia chromosome negative cd19 positive b-precursor all as part of the consolidation therapy (see section 4.

Flebogamma DIF (previously Flebogammadif) Euroopan unioni - suomi - EMA (European Medicines Agency)

flebogamma dif (previously flebogammadif)

instituto grifols s.a. - ihmisen normaali immunoglobuliini - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - immunoseerumit ja immunoglobuliinit, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Zenapax Euroopan unioni - suomi - EMA (European Medicines Agency)

zenapax

roche registration ltd. - daklitsumabia - graft rejection; kidney transplantation - immunosuppressantit - zenapax on tarkoitettu akuutin hylkimisreaktion de novo allogenic munuaisten transplantaation ennaltaehkäisyyn ja käytetään samanaikaisesti immunosuppressiivinen hoito, kuten siklosporiinin ja kortikosteroidien potilailla, jotka heitä, erittäin ovat ole rokotettu.

AQUAGEN SQ EPITEELIT  injektiokuiva-aine ja liuotin, liuosta varten Suomi - suomi - Fimea (Suomen lääkevirasto)

aquagen sq epiteelit injektiokuiva-aine ja liuotin, liuosta varten

alk-abello a/s - kissan karva,koiran karva,hevosen epiteeli - injektiokuiva-aine ja liuotin, liuosta varten - eläimet